{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:42:05Z","timestamp":1786995725540,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.pmr.2008.03.001","type":"journal-article","created":{"date-parts":[[2008,7,13]],"date-time":"2008-07-13T04:34:29Z","timestamp":1215923669000},"page":"573-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Nutrition and Dietary Supplements in Motor Neuron Disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Jeffrey","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s004150050578","article-title":"Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis","volume":"247","author":"Hardiman","year":"2000","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.53.5.1059","article-title":"Nutritional status is a prognostic factor for survival in ALS patients","volume":"53","author":"Desport","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.pmr.2008.03.001_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/BF00866922","article-title":"Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis","volume":"242","author":"Mazzini","year":"1995","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcn\/74.3.328","article-title":"Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis","volume":"74","author":"Desport","year":"2001","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"10.1016\/j.pmr.2008.03.001_bib5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.nmd.2006.04.005","article-title":"135th ENMC International Workshop: nutrition in amyotrophic lateral sclerosis 18-20 of March 2005, Naarden, The Netherlands","volume":"16","author":"Ludolph","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"3\u20134","key":"10.1016\/j.pmr.2008.03.001_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000089626","article-title":"Hypermetabolism in ALS: correlations with clinical and paraclinical parameters","volume":"2","author":"Desport","year":"2005","journal-title":"Neurodegener Dis"},{"issue":"6","key":"10.1016\/j.pmr.2008.03.001_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0148607104028006442","article-title":"Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis","volume":"28","author":"Sherman","year":"2004","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/14660820410020349","article-title":"Nutritional management in MND\/ALS patients: an evidence based review","volume":"5","author":"Heffernan","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"7","key":"10.1016\/j.pmr.2008.03.001_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1212\/WNL.52.7.1311","article-title":"Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force","volume":"52","author":"Miller","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/14660820410021258a","article-title":"Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis","volume":"6","author":"Desport","year":"2005","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.pmr.2008.03.001_bib11","unstructured":"Pacicco TJ, Lindblom S, Rosenfeld J. Enhancing PEG tube placement: a new device to maintain respiratory function during endoscopy in ALS patients. Paper presented at: International Motor Neuron Disease Symposium. Dublin, Ireland, December, 2005."},{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib12","first-page":"327","article-title":"Nutritional factors in the pathogenesis and therapy of respiratory insufficiency in neuromuscular diseases","volume":"48","author":"Aldrich","year":"1993","journal-title":"Monaldi Arch Chest Dis"},{"issue":"6","key":"10.1016\/j.pmr.2008.03.001_bib13","first-page":"631","article-title":"Nutritional issues and supplements in amyotrophic lateral sclerosis\u00a0and other neurodegenerative disorders","volume":"5","author":"Cameron","year":"2002","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajcn\/63.1.130","article-title":"Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death","volume":"63","author":"Kasarskis","year":"1996","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1212\/WNL.53.5.1123","article-title":"Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group","volume":"53","author":"Chio","year":"1999","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.pmr.2008.03.001_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0022-510X(99)00230-0","article-title":"A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials","volume":"169","author":"Kasarskis","year":"1999","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/jnnp.2003.020347","article-title":"Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS","volume":"75","author":"Chio","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14660820050515386","article-title":"Nutritional assessment and survival in ALS patients","volume":"1","author":"Desport","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14660820310011728","article-title":"Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction","volume":"4","author":"Mitsumoto","year":"2003","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.pmr.2008.03.001_bib20","unstructured":"Miller RG, Jackson CE, Kasarskis EJ, et\u00a0al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology, in press."},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/WNL.59.1.99","article-title":"Early symptom progression rate is related to ALS outcome: a prospective population-based study","volume":"59","author":"Chio","year":"2002","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/14660820510012013","article-title":"Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre","volume":"7","author":"Shaw","year":"2006","journal-title":"Amyotroph Lateral Scler"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/07315724.2001.10719010","article-title":"In the midst of confusion lies opportunity: fostering quality science in dietary supplement research","volume":"20","author":"Costello","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.pmr.2008.03.001_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/14660820410021249","article-title":"Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999","volume":"5","author":"Bradley","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"9","key":"10.1016\/j.pmr.2008.03.001_bib25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrn1971","article-title":"Molecular biology of amyotrophic lateral sclerosis: insights from genetics","volume":"7","author":"Pasinelli","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/14660820310011250","article-title":"Amyotrophic lateral sclerosis: a review of current concepts","volume":"4","author":"Strong","year":"2003","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/J157v05n03_03","article-title":"The use of herbal supplements and alternative therapies by\u00a0patients with amyotrophic lateral sclerosis (ALS)","volume":"5","author":"Vardeny","year":"2005","journal-title":"J Herb Pharmacother"},{"key":"10.1016\/j.pmr.2008.03.001_bib28","series-title":"Neurodegenerative diseases: neurobiology, pathogenesis, and therapeutics","author":"Beal","year":"2005"},{"key":"10.1016\/j.pmr.2008.03.001_bib29","first-page":"218","article-title":"Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants","volume":"5","author":"Singh","year":"2004","journal-title":"Journal of the Indian Academy of Clinical Medicine"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0197-4580(02)00078-7","article-title":"A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes","volume":"23","author":"Esposito","year":"2002","journal-title":"Neurobiol Aging"},{"issue":"9","key":"10.1016\/j.pmr.2008.03.001_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00002512-200118090-00004","article-title":"Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment","volume":"18","author":"Halliwell","year":"2001","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410390203","article-title":"Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis","volume":"39","author":"Gurney","year":"1996","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib33","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1046\/j.1471-4159.1997.69052064.x","article-title":"Evidence of increased oxidative damage in\u00a0both sporadic and familial amyotrophic lateral sclerosis","volume":"69","author":"Ferrante","year":"1997","journal-title":"J Neurochem"},{"issue":"7","key":"10.1016\/j.pmr.2008.03.001_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0891-5849(00)00349-X","article-title":"Increased oxidative damage to DNA in ALS patients","volume":"29","author":"Bogdanov","year":"2000","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(00)00365-8","article-title":"Blood oxidative stress in amyotrophic lateral sclerosis","volume":"178","author":"Bonnefont-Rousselot","year":"2000","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002829.pub3","article-title":"Antioxidant treatment for amyotrophic lateral sclerosis\/motor neuron disease","author":"Orrell","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0163-7258(98)00042-4","article-title":"The role of excitotoxicity in neurodegenerative disease: implications for therapy","volume":"81","author":"Doble","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.pmr.2008.03.001_bib38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF03160574","article-title":"Glutamate, excitotoxicity and amyotrophic lateral sclerosis","volume":"244","author":"Shaw","year":"1997","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.pmr.2008.03.001_bib39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0197-0186(01)00125-5","article-title":"Mitochondrial involvement in amyotrophic lateral sclerosis","volume":"40","author":"Menzies","year":"2002","journal-title":"Neurochem Int"},{"issue":"1\u20132","key":"10.1016\/j.pmr.2008.03.001_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jns.2007.09.038","article-title":"Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis","volume":"267","author":"Murata","year":"2008","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(98)00046-0","article-title":"An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration","volume":"29","author":"Cassarino","year":"1999","journal-title":"Brain Res Brain Res Rev"},{"issue":"Suppl 1","key":"10.1016\/j.pmr.2008.03.001_bib42","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1007\/BF03161151","article-title":"Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis","volume":"247","author":"Shaw","year":"2000","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib43","first-page":"25","article-title":"Mitochondrial medicine\u2013molecular pathology of defective oxidative phosphorylation","volume":"31","author":"Fosslien","year":"2001","journal-title":"Ann Clin Lab Sci"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib44","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1046\/j.1471-4159.1995.64051965.x","article-title":"Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture","volume":"64","author":"Bolanos","year":"1995","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/cne.20130","article-title":"Intrinsic differences in brain and spinal cord\u00a0mitochondria: Implication for therapeutic interventions","volume":"474","author":"Sullivan","year":"2004","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pmr.2008.03.001_bib46","unstructured":"Panov A, Rosenfeld J. Glutamate enhances mitochondrial ATP production and ROS generation in nonsynaptic brain and spinal cord mitochondria of the wild type and SOD1 mutant rats. Paper presented at: International Symposium on Motor Neuron Disease. Toronto, Canada, 2007."},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archneur.1997.00550170013008","article-title":"Lou Gehrig and amyotrophic lateral sclerosis. Is vitamin E to be revisited?","volume":"54","author":"Reider","year":"1997","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/10284150290028954","article-title":"Vitamin E and neurodegenerative disorders associated with oxidative stress","volume":"5","author":"Butterfield","year":"2002","journal-title":"Nutr Neurosci"},{"key":"10.1016\/j.pmr.2008.03.001_bib49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.mam.2007.01.004","article-title":"D. Vitamin E and neurodegenerative diseases","volume":"28","author":"Ricciarelli","year":"2007","journal-title":"Mol Aspects Med"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0147-49-17","article-title":"Vitamin E deficiency and risk of equine motor neuron disease","volume":"49","author":"Mohammed","year":"2007","journal-title":"Acta Vet Scand"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1939-1676.2001.tb01241.x","article-title":"Canine motor neuron disease: clinicopathologic features and selected indicators of oxidative stress","volume":"15","author":"Green","year":"2001","journal-title":"J Vet Intern Med"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0899-9007(98)00167-1","article-title":"A vitamin E-deficient diet affects nerve regeneration in rats","volume":"15","author":"Enrione","year":"1999","journal-title":"Nutrition"},{"issue":"6\u20137","key":"10.1016\/j.pmr.2008.03.001_bib53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s007020050089","article-title":"Cerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosis","volume":"105","author":"de Bustos","year":"1998","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0022-510X(95)00145-R","article-title":"E levels are normal in amyotrophic lateral sclerosis","volume":"132","author":"Iwasaki","year":"1995","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.20316","article-title":"Vitamin E intake and risk of amyotrophic lateral sclerosis","volume":"57","author":"Ascherio","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pmr.2008.03.001_bib56","doi-asserted-by":"crossref","unstructured":"Veldink JH, Kalmijn S, Groeneveld GJ, et\u00a0al. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis [erratum appears in J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):779]. 2007;78(4):367\u201371.","DOI":"10.1136\/jnnp.2005.083378"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/146608201300079364","article-title":"A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group","volume":"2","author":"Desnuelle","year":"2001","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"Suppl 1","key":"10.1016\/j.pmr.2008.03.001_bib58","first-page":"101","volume":"35","author":"Kwiecinski","year":"2001","journal-title":"Neurol Neurochir Pol"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00702-004-0220-1","article-title":"High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study","volume":"112","author":"Graf","year":"2005","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10072-006-0668-x","article-title":"Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study","volume":"27","author":"Galbussera","year":"2006","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib61","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1212\/01.wnl.0000297193.53986.6f","article-title":"Elevated plasma homocysteine levels in patients with amytrophic lateral sclerosis","volume":"70","author":"Zoccolella","year":"2008","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.pmr.2008.03.001_bib62","doi-asserted-by":"crossref","first-page":"13435","DOI":"10.1074\/jbc.271.23.13435","article-title":"Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with atp-dependent glutamate uptake","volume":"271","author":"Xu","year":"1996","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1006\/bbrc.1999.0577","article-title":"Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke","volume":"258","author":"Trieu","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.pmr.2008.03.001_bib64","first-page":"1141","volume":"59","author":"Izumi","year":"2007","journal-title":"Brain Nerve"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17482960701249241","article-title":"Role of zinc in ALS","volume":"8","author":"Smith","year":"2007","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neulet.2003.08.062","article-title":"Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"352","author":"Groeneveld","year":"2003","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neulet.2004.12.045","article-title":"Protection by dietary zinc in ALS mutant G93A SOD transgenic mice","volume":"379","author":"Ermilova","year":"2005","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1034\/j.1600-079X.2002.02943.x","article-title":"Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients","volume":"33","author":"Jacob","year":"2002","journal-title":"J Pineal Res"},{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-079X.2006.00377.x","article-title":"Reduced oxidative damage in ALS by high-dose enteral melatonin treatment","volume":"41","author":"Weishaupt","year":"2006","journal-title":"J Pineal Res"},{"issue":"Suppl 4","key":"10.1016\/j.pmr.2008.03.001_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14660820050515665","article-title":"Creatine and coenzyme Q10 in the treatment of ALS","volume":"1","author":"Strong","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord."},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib71","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/6568","article-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis","volume":"5","author":"Klivenyi","year":"1999","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1471-4159.2001.00188.x","article-title":"Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation","volume":"77","author":"Andreassen","year":"2001","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib73","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0969-9961(03)00041-X","article-title":"Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment","volume":"13","author":"Derave","year":"2003","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib74","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0306-4522(03)00212-4","article-title":"Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice","volume":"119","author":"Snow","year":"2003","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib75","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ana.10476","article-title":"Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS","volume":"53","author":"Zhang","year":"2003","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pmr.2008.03.001_bib76","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1471-4159.2003.02160.x","article-title":"Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"88","author":"Klivenyi","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pmr.2008.03.001_bib77","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis","volume":"43","author":"Groeneveld","year":"2003","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.pmr.2008.03.001_bib78","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pmr.2008.03.001_bib79","unstructured":"Rosenfeld J, King R, Jackson C, et\u00a0al. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler Other Motor Neuron Disord, in press."},{"issue":"Suppl","key":"10.1016\/j.pmr.2008.03.001_bib80","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1016\/j.mito.2007.01.004","article-title":"Coenzyme Q treatment of neurodegenerative diseases of aging","volume":"7","author":"Galpern","year":"2007","journal-title":"Mitochondrion"},{"issue":"8\u20139","key":"10.1016\/j.pmr.2008.03.001_bib81","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s007020070050","article-title":"Serum levels of coenzyme Q10 in patients with amyotrophic lateral sclerosis","volume":"107","author":"Molina","year":"2000","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2004.09.030","article-title":"An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients","volume":"228","author":"Sohmiya","year":"2005","journal-title":"J Neurol Sci"},{"issue":"11","key":"10.1016\/j.pmr.2008.03.001_bib83","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","article-title":"Tolerance of high-dose (3,000 mg\/day) coenzyme Q10 in ALS","volume":"65","author":"Ferrante","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.pmr.2008.03.001_bib84","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1212\/01.wnl.0000201182.60750.66","article-title":"A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS","volume":"66","author":"Levy","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exnr.2001.7633","article-title":"Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice","volume":"168","author":"Andreassen","year":"2001","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib86","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.brainres.2005.11.052","article-title":"L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis","volume":"1070","author":"Kira","year":"2006","journal-title":"Brain Res"},{"issue":"6","key":"10.1016\/j.pmr.2008.03.001_bib87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF02341783","article-title":"Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial","volume":"19","author":"Chio","year":"1998","journal-title":"Ital J Neurol Sci"},{"issue":"7","key":"10.1016\/j.pmr.2008.03.001_bib88","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1212\/WNL.52.7.1492","article-title":"The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis","volume":"52","author":"Cudkowicz","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pmr.2008.03.001_bib89","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archneur.1995.00540300031009","article-title":"Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis","volume":"52","author":"Louwerse","year":"1995","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.pmr.2008.03.001_bib90","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1097\/00001756-200008030-00029","article-title":"N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis","volume":"11","author":"Andreassen","year":"2000","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ana.410440229","article-title":"The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"44","author":"Jaarsma","year":"1998","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"10.1016\/j.pmr.2008.03.001_bib92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0022-510X(00)00421-4","article-title":"Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice","volume":"180","author":"Jiang","year":"2000","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.pmr.2008.03.001_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/JMN:17:1:89","article-title":"Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"17","author":"Ferrante","year":"2001","journal-title":"J Mol Neurosci"},{"issue":"4","key":"10.1016\/j.pmr.2008.03.001_bib94","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/1531-8249(200010)48:4<686::AID-ANA21>3.0.CO;2-H","article-title":"Lyophilized red wine administration prolongs survival in an animal model of amyotrophic lateral sclerosis","volume":"48","author":"Esposito","year":"2000","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.pmr.2008.03.001_bib95","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s11064-006-9166-z","article-title":"Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"31","author":"Xu","year":"2006","journal-title":"Neurochem Res"},{"issue":"2","key":"10.1016\/j.pmr.2008.03.001_bib96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neulet.2005.10.056","article-title":"The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice","volume":"395","author":"Koh","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pmr.2008.03.001_bib97","unstructured":"Cowper W. (English poet 1731\u20131800)."}],"container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965108000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965108000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T03:32:28Z","timestamp":1760931148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047965108000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S1047965108000259"],"URL":"https:\/\/doi.org\/10.1016\/j.pmr.2008.03.001","relation":{},"ISSN":["1047-9651"],"issn-type":[{"value":"1047-9651","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutrition and Dietary Supplements in Motor Neuron Disease","name":"articletitle","label":"Article Title"},{"value":"Physical Medicine and Rehabilitation Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmr.2008.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}